Sergeeva Olga, Zhang Yifan, Julian Willian, Sasikumar Arun, Awadallah Amad, Kenyon Jonathan, Shi Wuxian, Sergeev Maxim, Huang Steve, Sexton Sandra, Iyer Renuka, Xin Wei, Avril Norbert, Chan Ernest Ricky, Lee Zhenghong
Radiology, Case Western Reserve University, Cleveland, Ohio.
Nuclear Medicine, St. Gregorios International Cancer Care Centre, Parumala, Kerala, India.
Gastro Hep Adv. 2022;1(4):631-639. doi: 10.1016/j.gastha.2022.04.014. Epub 2022 Apr 28.
Radiolabeled short peptide ligands targeting prostate-specific membrane antigen (PSMA) were developed initially for imaging and treatment of prostate cancers. While many nonprostate solid tumors including hepatocellular carcinoma (HCC) express little PSMA, their neovasculature expresses a high level of PSMA, which is avid for Gallium-68-labeled PSMA-targeting radio-ligand (Ga-PSMA-11) for positron emission tomography (PET). However, the lack of a spontaneous animal model of tumor-associated vascular PSMA overexpression has hindered the development and assessment of PSMA-targeting radioligands for imaging and therapy of the nonprostatic cancers. We identified detectable indigenous PSMA expression on tumor neovascular endothelia in a naturally occurring woodchuck model of HCC.
Molecular docking was performed with 3 bait PSMA ligands and compared between human and woodchuck PSMA. Initially, PET images were acquired dynamically after intravenously injecting 37 MBq (1.0 mCi) of Ga-PSMA-11 into woodchuck models of HCC. Subsequently, 10-minute static PET scans were conducted for other animals 1-hour after injection due to HCC and liver background uptake stabilization at 30-45 minutes after injection. Liver tissue samples were harvested after imaging, fresh-frozen for quantitative reverse transcription polymerase chain reaction and western blot for validation, or fixed for histology for correlation.
Our preclinical studies confirmed the initial clinical findings of Ga-PSMA-11 uptake in HCC. The agents (ligands and antibodies) developed against human PSMA were found to be reactive against the woodchuck PSMA.
This animal model offers a unique opportunity for investigating the biogenesis of tumor-associated vascular PSMA, its functional role(s), and potentials for future treatment strategies targeting tumor vascular PSMA using already developed PSMA-targeting agents.
放射性标记的靶向前列腺特异性膜抗原(PSMA)的短肽配体最初是为前列腺癌的成像和治疗而开发的。虽然包括肝细胞癌(HCC)在内的许多非前列腺实体瘤几乎不表达PSMA,但其新生血管表达高水平的PSMA,该PSMA对用于正电子发射断层扫描(PET)的68Ga标记的靶向PSMA放射性配体(Ga-PSMA-11)具有很高的亲和力。然而,缺乏肿瘤相关血管PSMA过表达的自发动物模型阻碍了用于非前列腺癌成像和治疗的靶向PSMA放射性配体的开发和评估。我们在自然发生的土拨鼠HCC模型中发现肿瘤新生血管内皮细胞上可检测到内源性PSMA表达。
用3种诱饵PSMA配体进行分子对接,并在人和土拨鼠PSMA之间进行比较。最初,在向土拨鼠HCC模型静脉注射37 MBq(1.0 mCi)的Ga-PSMA-11后动态采集PET图像。随后,由于注射后30 - 45分钟HCC和肝脏本底摄取稳定,在注射后1小时对其他动物进行10分钟的静态PET扫描。成像后采集肝脏组织样本,新鲜冷冻用于定量逆转录聚合酶链反应和蛋白质免疫印迹验证,或固定用于组织学相关性分析。
我们的临床前研究证实了Ga-PSMA-11在HCC中摄取的初步临床发现。发现针对人PSMA开发的试剂(配体和抗体)对土拨鼠PSMA有反应。
该动物模型为研究肿瘤相关血管PSMA的生物发生、其功能作用以及使用已开发的靶向PSMA药物靶向肿瘤血管PSMA的未来治疗策略的潜力提供了独特的机会。